BRAF gene copy number and mutant allele frequency correlate with time to progression in metastatic melanoma patients treated with MAPK inhibitors.

Metastatic melanoma is characterized by complex genomic alterations including a high rate of mutations in driver genes and widespread deletions and amplifications encompassing various chromosome regions. Among them, chromosome 7 is frequently gained in BRAF mutant melanoma, inducing a mutant allele-specific imbalance. Although BRAF amplification is a known mechanism of acquired resistance to therapy with MAPK inhibitors, it is still unclear if BRAF copy number variation and BRAF mutant allele imbalance at baseline can be associated with response to treatment. In this study, we used a multimodal approach to assess BRAF copy number and mutant allele frequency in pre-treatment melanoma samples from 46 patients who received MAPK inhibitor-based therapy and we analyzed the association with progression free survival. We found that 65% patients displayed BRAF gains, often supported by chromosome 7 polysomy. In addition, we observed that 64% patients had a balanced BRAF mutant/wild-type allele ratio, while 14% and 23% patients had low and high BRAF mutant allele frequency, respectively. Notably, a significantly higher risk of progression was observed in patients with a diploid BRAF status vs. those with BRAF gains (HR = 2.86; 95% CI 1.29-6.35; p = 0.01) and in patients with low percentage vs. those with a balanced BRAF mutant allele percentage (HR = 4.54, 95% CI 1.33-15.53; p = 0.016). Our data suggest that quantitative analysis of the BRAF gene could be useful to select the melanoma patients who are most likely to benefit from therapy with MAPK inhibitors.

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader https://ift.tt/2H1J4Xi